Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29750685 | 1.00 | HSD17B10 (0.54) | HSD17B10PTGS1AKR1C3AKR1C2KDM4E | |
| SCHEMBL24744927 | 0.89 | KDM4E (0.58) | HSD17B10PTGS1AKR1C3AKR1C2KDM4E | |
| SCHEMBL24745619 | 0.83 | KDM4E (0.47) | HSD17B10KDM4EALDH1A1GFERHPGD | |
| SCHEMBL1574696 | 0.82 | KDM4E (0.70) | HSD17B10KDM4EALDH1A1GFERHPGD | |
| SCHEMBL24597746 | 0.81 | KDM4E (0.45) | HSD17B10KDM4EALDH1A1GFERHPGD | |
| SCHEMBL24597630 | 0.79 | ALDH1A1 (0.43) | HSD17B10KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL1574405 | 0.79 | KDM4E (0.58) | HSD17B10KDM4EALDH1A1GFERHPGD | |
| SCHEMBL1574753 | 0.79 | ALDH1A1 (0.72) | HSD17B10KDM4EALDH1A1GFERHPGD | |
| SCHEMBL12677805 | 0.78 | ALDH1A1 (0.54) | HSD17B10KDM4EALDH1A1GFERHPGD | |
| SCHEMBL2945200 | 0.78 | ALDH1A1 (0.67) | HSD17B10KDM4EALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307547-A1 | NOVEL COMPOUNDS WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-19 | — | — | US | disclosed |
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| CN-117957218-A | Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins | 凯普托尔治疗学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-4347579-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2024-04-10 | — | — | EP | disclosed |
| EP-4271670-A1 | NOVEL COMPOUNDS WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | Captor Therapeutics S.A. (PL) | 2023-11-08 | — | — | EP | disclosed |
| CN-116917275-A | Novel CEREBLON-binding compounds and methods of use thereof | 凯普托尔治疗学股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022144416-A1 | NOVEL COMPOUNDS WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022144416-A1 | NOVEL COMPOUNDS WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2022-07-07 | — | — | WO | disclosed |
| US-20050272736-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| US-20050272728-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005113536-A2 | TRI- AND BI-CYCLIC HETEROARYL HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005113551-A1 | BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS | ABBOTT LABORATORIES (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050256309-A1 | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBOTT LABORATORIES | 2005-11-17 | — | — | US | disclosed |
| US-20050256118-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | ABBOTT LABORATORIES | 2005-11-17 | — | — | US | disclosed |
| EP-1569637-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004043458-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040092521-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272736-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | HRH3, HRH4, HRH2 | HSD17B10 3354/4885PTGS1 1286/4885AKR1C3 499/4885 |
| US-20050272728-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | HRH3, HRH4, HRH2 | HSD17B10 3795/4885PTGS1 1586/4885AKR1C3 343/4885 |
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | MCL1, MDM2, XIAP | HSD17B10 3206/4885PTGS1 4224/4885AKR1C3 2179/4885 |
| US-20050256118-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | HRH3, HRH4, HRH2 | HSD17B10 3795/4885PTGS1 1586/4885AKR1C3 343/4885 |
| US-20050256309-A1 | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands | HRH3, HRH4, HRH2 | HSD17B10 3354/4885PTGS1 1286/4885AKR1C3 499/4885 |
| US-20040092521-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | HSD17B10 2966/4885PTGS1 442/4885AKR1C3 608/4885 |
| US-20240307547-A1 | NOVEL COMPOUNDS WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CRBN, CDR2, FABP7 | HSD17B10 2592/4885PTGS1 3840/4885AKR1C3 2367/4885 |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | HSD17B10 2877/4885PTGS1 577/4885AKR1C3 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.